Receptor binding peptides for target-selective delivery of nanoparticles encapsulated drugs

被引:77
作者
Accardo, Antonella [1 ,2 ]
Aloj, Luigi [3 ]
Aurilio, Michela [3 ]
Morelli, Giancarlo [1 ,2 ]
Tesauro, Diego [1 ,2 ]
机构
[1] Univ Naples Federico II, Dept Pharm, CIRPeB, Naples, Italy
[2] Univ Naples Federico II, IBB CNR, Naples, Italy
[3] Fdn G Pascale, Ist Nazl Studio & Cura Tumori, Dept Nucl Med, Naples, Italy
来源
INTERNATIONAL JOURNAL OF NANOMEDICINE | 2014年 / 9卷
关键词
receptors binding peptides; drug delivery; nanoparticles; supramolecular aggregates; active targeting; CARBOXYMETHYL CHITOSAN MICELLES; POSITRON-EMISSION-TOMOGRAPHY; GASTRIN-RELEASING-PEPTIDE; BLOCK-COPOLYMER MICELLES; IN-VIVO EVALUATION; N-OCTYL-O; GOLD NANOPARTICLES; MAGNETIC NANOPARTICLES; LIPOSOMAL DOXORUBICIN; MULTIDRUG-RESISTANCE;
D O I
10.2147/IJN.S53593
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
Active targeting by means of drug encapsulated nanoparticles decorated with -targeting bioactive moieties represents the next frontier in drug delivery; it reduces drug side effects and increases the therapeutic index. Peptides, based on their chemical and biological properties, could have a prevalent role to direct drug encapsulated nanoparticles, such as liposomes, micelles, or hard nanoparticles, toward the tumor tissues. A considerable number of molecular targets for peptides are either exclusively expressed or overexpressed on both cancer vasculature and cancer cells. They can be classified into three wide categories: integrins; growth factor receptors (GFRs); and G-protein coupled receptors (GPCRs). Therapeutic agents based on nanovectors decorated with peptides targeting membrane receptors belonging to the GPCR family overexpressed by cancer cells are reviewed in this article. The most studied targeting membrane receptors are considered: somatostatin receptors; cholecystokinin receptors; receptors associated with the Bombesin like peptides family; luteinizing hormone-releasing hormone receptors; and neurotensin receptors. Nanovectors of different sizes and shapes (micelles, liposomes, or hard nanoparticles) loaded with doxorubicin or other cytotoxic drugs and externally functionalized with natural or synthetic peptides are able to target the overexpressed receptors and are described based on their formulation and in vitro and in vivo behaviors.
引用
收藏
页码:1537 / 1557
页数:21
相关论文
共 110 条
[31]   Quantitative Evaluation of Bioorthogonal Chemistries for Surface Functionalization of Nanoparticles [J].
Feldborg, Lise N. ;
Jolck, Rasmus I. ;
Andresen, Thomas L. .
BIOCONJUGATE CHEMISTRY, 2012, 23 (12) :2444-2450
[32]  
Foss F M, 2000, Clin Lymphoma, V1, P110, DOI 10.3816/CLM.2000.n.009
[33]  
Frimpong RA, 2010, NANOMEDICINE-UK, V5, P1401, DOI [10.2217/nnm.10.114, 10.2217/NNM.10.114]
[34]   LIPOSOME CIRCULATION TIME AND TUMOR TARGETING - IMPLICATIONS FOR CANCER-CHEMOTHERAPY [J].
GABIZON, AA .
ADVANCED DRUG DELIVERY REVIEWS, 1995, 16 (2-3) :285-294
[35]   Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors [J].
Ginj, Mihaela ;
Zhang, Hanwen ;
Waser, Beatrice ;
Cescato, Renzo ;
Wild, Damian ;
Wang, Xuejuan ;
Erchegyi, Judit ;
Rivier, Jean ;
Maecke, Helmut R. ;
Reubi, Jean Claude .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (44) :16436-16441
[36]   PEPTIDES IN BRAIN - NEW ENDOCRINOLOGY OF NEURON [J].
GUILLEMIN, R .
SCIENCE, 1978, 202 (4366) :390-402
[37]  
He YN, 2010, INT J NANOMED, V5, P697
[38]   Targeting properties of peptide-modified radiolabeled liposomal nanoparticles [J].
Helbok, Anna ;
Rangger, Christine ;
von Guggenberg, Elisabeth ;
Saba-Lepek, Matthias ;
Radolf, Thorsten ;
Thurner, Gudrun ;
Andreae, Fritz ;
Prassl, Ruth ;
Decristoforo, Clemens .
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2012, 8 (01) :112-118
[39]   The Vps10p-domain receptor family [J].
Hermey, Guido .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2009, 66 (16) :2677-2689
[40]   Folate receptor-mediated drug targeting: From therapeutics to diagnostics [J].
Hilgenbrink, AR ;
Low, PS .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2005, 94 (10) :2135-2146